"Another targeted agent for non-small-cell lung cancer (NSCLC) that is positive for the ALK rearrangement (found in about 5% of NSCLC patients) has just been approved by the US Food and Drug Administration (FDA). The new drug, alectinib ("...
Iressa Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Iressa (gefitinib) is a tyrosine kinase inhibitor used for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Common side effects of Iressa include:
- skin reactions,
- nail disorders,
- inflammation of the mouth lining,
- decreased appetite,
- eyelid swelling, and
- dry eye.
Tell your doctor if you have unlikely but serious side effects of Iressa including:
- unusual bleeding (coughing up blood, blood in urine),
- eye irritation or pain, or
- swelling of the ankles or feet.
The recommended dose of Iressa is 250 mg orally, once daily with or without food. Iressa may interact with rifampicin, phenytoin, tricyclic antidepressants, azole antifungals, proton pump inhibitors (PPIs), histamine H2-receptor antagonists, antacids, and warfarin. Tell your doctor all medications and supplements you use. Iressa is not recommended for use during pregnancy. It may harm a fetus or result in fetal death. It is unknown if Iressa passes into breast milk, however, Iressa is not recommended for use while breastfeeding.
Our Iressa (gefitinib) Tablets Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Iressa in Detail - Patient Information: Side Effects
If you experience any of the following serious side effects from gefitinib, contact your doctor immediately:
- an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
- lung problems (difficulty breathing, shortness of breath, increased coughing, fever, or chest pain);
- severe or persistent nausea, vomiting, loss of appetite, or diarrhea; or
- eye pain or irritation.
Other, less serious side effects may be more likely to occur. Continue taking gefitinib and talk to your doctor if you experience:
- mild to moderate nausea, vomiting, loss of appetite, or diarrhea;
- skin rash, dryness, itching, or acne; or
Other side effects have also been reported. Discuss with your doctor any side effect that occurs during treatment with gefitinib. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Iressa (Getfitinib)
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Iressa Overview - Patient Information: Side Effects
Diarrhea, rash, acne, nausea, vomiting, loss of appetite, nail problems, hair loss, red/sore mouth or throat, or unusual weakness may occur. If any of these effects persist or worsen, notify your doctor or pharmacist immediately.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Persistent nausea, vomiting, diarrhea, or loss of appetite may result in a serious loss of body water (dehydration) and kidney problems. Contact your doctor promptly if you notice any symptoms of dehydration, such as: unusual decreased urination, unusual dry mouth/thirst, fast heartbeat, dizziness/lightheadedness.
Tell your doctor immediately if any of these unlikely but serious side effects occur: unusual bleeding (coughing up blood, blood in urine), eye irritation/pain, swelling of the ankles/feet.
Gefitinib may cause rare (possibly fatal) lung disease (interstitial lung disease-ILD). Tell your doctor immediately if you develop trouble breathing, cough or fever.
If you have persistent diarrhea or skin rashes contact your doctor. Your doctor may temporarily stop gefitinib (for up to 14 days) which may help reverse those side effects. Treatment is then resumed with the same dosage.
An allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of an allergic reaction include: severe rash, itching/swelling (especially of the face/tongue/throat), dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Iressa (Getfitinib)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Iressa FDA Prescribing Information: Side Effects
The following adverse drug reactions are discussed in more detail in other sections of the labeling:
- Interstitial Lung Disease [see WARNINGS AND PRECAUTIONS]
- Hepatotoxicity [see WARNINGS AND PRECAUTIONS]
- Gastrointestinal Perforation [see WARNINGS AND PRECAUTIONS]
- Severe or Persistent Diarrhea [see WARNINGS AND PRECAUTIONS]
- Ocular Disorders including Keratitis [see WARNINGS AND PRECAUTIONS]
- Bullous and Exfoliative Skin Disorders [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of IRESSA is based on the data from 2462 patients with NSCLC who received IRESSA 250 mg daily monotherapy in three randomized clinical studies (Study 2, Study 3 and Study 4). Patients with a history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis that required steroid treatment or any evidence of clinically active interstitial lung disease were excluded from these studies.
Study 2 was a randomized, multicenter, open-label trial in which 1217 patients were randomized to receive first-line treatment for metastatic NSCLC; 607 patients received IRESSA 250 mg daily and 589 patients received carboplatin/paclitaxel. The median duration of treatment with IRESSA was 5.9 months. The study population characteristics were: median age 57 years, age less than 65 years (73%), female (79%), Asian (100%), NSCLC adenocarcinoma histology (100%), never smoker (94%), light ex-smoker (6%), ECOG PS 0 or 1 (90%).
Study 3 was a randomized, multicenter, double-blind, placebo-controlled trial in which 1692 patients were randomized to receive second- or third-line treatment for metastatic NSCLC; of which 1126 patients received IRESSA 250 mg daily and 562 patients received placebo. The median duration of treatment with IRESSA was 2.9 months. The study population characteristics were: median age 62 years, age less than 65 years (60%), female (33%), Caucasian (75%), Asian (21%), NSCLC adenocarcinoma histology (48%), never smoker (22%), ECOG PS 0 or 1 (65%), PS 2 (29%), PS 3 (5%) and two or more prior therapies (51%).
Study 4 was a randomized, multicenter, open-label trial in which 1466 patients were randomized to receive second-line treatment for metastatic NSCLC; 729 patients received IRESSA 250 mg daily and 715 patients received docetaxel. The median duration of treatment with IRESSA was 2.4 months. The study population characteristics were: median age 61 years, age less than 65 years (61%), female (36%), Caucasian (79%), Asian (21%), NSCLC adenocarcinoma histology (54%), never smoker (20%), ECOG PS 0 or 1 (88%) and two or more prior therapies (16%).
The pooled safety database from the three randomized trials was used to evaluate for serious and uncommon adverse drug reactions. Common adverse reactions were evaluated in Study 3. The most frequent adverse reactions in Study 3 (incidence of > 20% and greater than placebo) reported in IRESSA-treated patients were skin reactions (47%) and diarrhea (29%). The most frequent fatal adverse reactions in IRESSA-treated patients were respiratory failure (0.9%), pneumonia (0.8%), and pulmonary embolism (0.5%).
Approximately 5% of IRESSA-treated patients and 2.3% of placebo-treated patients discontinued treatment due to an adverse event. The most frequent adverse reactions that led to discontinuation in patients treated with IRESSA were nausea (0.5%), vomiting (0.5%) and diarrhea (0.4%).
Table 1: Selected Adverse Drug Reactions Occurring
with an Incidence Rate ≥ 5% and an Increase of > 2% of IRESSA-treated
Patients in Study 3
|Adverse Reaction||Percentage (%) of patients|
|All Grades||Grade 3 and 4||All Grades||Grade 3 and 4|
|Skin and subcutaneous tissue disorders|
|Metabolism and nutrition disorders|
|1 Includes Acne, Acne pustular, Dermatitis,
Dermatitis acneiform, Dermatitis exfoliative, Drug eruption, Dry skin,
Erythema, Exfoliative rash, Folliculitis, Pruritus, Pruritus generalized, Rash,
Rash erythematous, Rash generalized, Rash macular, Rash maculo-papular, Rash
papular, Rash pruritic, Rash pustular, Rash vesicular, Skin exfoliation, Skin
2 Includes Ingrowing nail, Nail bed infection, Nail disorder, Nail infection, Onychoclasis, Onycholysis, Paronychia
3 Includes Diarrhea, Feces soft, Frequent bowel movements
4 Includes Aphthous stomatitis, Cheilitis, Glossodynia, Mouth ulceration, Mucosal inflammation, Oral mucosal blistering, Stomatitis, Tongue disorder, Tongue ulceration
5 Includes Blepharitis, Conjunctival hyperemia, Conjunctivitis, Dry eye, Eye irritation, Eye pruritus, Eye swelling, Eyelid irritation, Eyelid edema, Eyelids pruritus
Table 2 : Treatment Emergent Laboratory Abnormalities
Occurring More Frequently in IRESSA- Treated Patients in Study 3
|All Grades %||Grade 3 and 4 %||All Grades %||Grade 3 and 4 %|
|Alanine aminotransferase increased1||38%2||2.4%||23%2||1.4%4|
|Aspartate aminotransferase increased1||40%3||2.0%||25%3||1.3%5|
|1Patients were allowed to enter the clinical study with lab
values of ALT or AST CTCAE grade 1 or 2
2 14% gefitinib patients and 10% placebo patients were CTC grade 1 or 2 ALT at baseline
3 15% gefitinib patients and 12% placebo patients were CTC grade 1 or 2 AST at baseline
4 0.2% of placebo patients were CTC grade 3 at baseline
5 0.4% of placebo patients were CTC grade 3 at baseline
The following adverse reactions have been reported with IRESSA across NSCLC trials (Study 2, Study 3 and Study 4) and are not listed elsewhere in Section 6: nausea (18%), asthenia (17%), pyrexia (9%), alopecia (4.7%), hemorrhage (including epistaxis and hematuria) (4.3%), dry mouth (2%), dehydration (1.8%), allergic reactions including angioedema and urticaria (1.1%), elevations in blood creatinine (1.5%), and pancreatitis (0.1%).
The following adverse reactions have been identified during post-approval use of IRESSA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for Iressa (Getfitinib)
Additional Iressa Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.